Scynexis (SCYX) Other Non-Current Liabilities (2013 - 2026)
Scynexis' (SCYX) quarterly Other Non-Current Liabilities came in at $18.9 million in Q1 2026, up 270.59% YoY from $5.1 million in Q1 2025, and up 759.09% on a QoQ basis from $2.2 million in Q4 2025.
Scynexis (SCYX) Other Non-Current Liabilities (2013 - 2026) Analysis & Trends
Scynexis (SCYX) has 13 years of Other Non-Current Liabilities data on file, last reported at $18.9 million in Q1 2026.
- Quarterly Other Non-Current Liabilities rose 270.59% year-over-year to $18.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.9 million (up 270.59% YoY) and the FY2025 annual result came in at $2.2 million, down 72.5% from the prior year.
- Other Non-Current Liabilities grew to $18.9 million in Q1 2026, from $2.2 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $40.3 million in Q1 2023 to a low of $2.2 million in Q4 2025.
- A 5-year average of $15.2 million and a median of $12.2 million in 2024 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities soared 5557.86% — and 2025, when it plunged 83.89%.
- Tracing SCYX's Other Non-Current Liabilities over 5 years: stood at $18.6 million in 2022, then increased by 16.56% to $21.7 million in 2023, then tumbled by 63.1% to $8.0 million in 2024, then plunged by 72.5% to $2.2 million in 2025, then jumped by 759.09% to $18.9 million in 2026.
- The last three Other Non-Current Liabilities figures came in at $18.9 million (Q1 2026), $2.2 million (Q4 2025), and $3.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Scynexis | 61.37 Mn | -53.33 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 800,000.00 |
| Mar 31, 2026 | 18.90 Mn |
| Dec 31, 2025 | 2.20 Mn |
| Sep 30, 2025 | 3.54 Mn |
| Jun 30, 2025 | 2.90 Mn |
| Mar 31, 2025 | 5.10 Mn |
| Dec 31, 2024 | 8.00 Mn |
| Sep 30, 2024 | 11.21 Mn |
| Jun 30, 2024 | 18.00 Mn |
| Mar 31, 2024 | 12.20 Mn |
| Dec 31, 2023 | 21.68 Mn |
| Sep 30, 2023 | 24.60 Mn |
| Jun 30, 2023 | 30.09 Mn |
| Mar 31, 2023 | 40.32 Mn |
| Dec 31, 2022 | 18.60 Mn |
| Sep 30, 2022 | 27.73 Mn |
| Jun 30, 2022 | 5.06 Mn |
| Mar 31, 2022 | 7.92 Mn |
| Dec 31, 2021 | 3.35 Mn |
| Sep 30, 2021 | 2.10 Mn |